Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions

Gastroenterology

Volumn 152, Issue 6, 2017, Pages 1297-1309

  Loomba, Rohit ^a   Liang, T Jake ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Chronic Hepatitis B; Cirrhosis; Fulminant Hepatic Failure; Guidelines; Liver Disease; Liver Failure; Mortality; Viral Hepatitis

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; PROTEASOME INHIBITOR; PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR;

ACUTE LIVER FAILURE; ANTIVIRAL THERAPY; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; GASTROINTESTINAL STROMAL TUMOR; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; MORBIDITY; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; POPULATION; PRIORITY JOURNAL; REVIEW; SCREENING TEST; TREATMENT DURATION; VIREMIA; VIRUS REACTIVATION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; HEPATITIS B, CHRONIC; PHYSIOLOGY; RISK FACTOR; SECONDARY PREVENTION; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEASOME INHIBITORS; PROTEIN KINASE INHIBITORS; RISK FACTORS; RITUXIMAB; SECONDARY PREVENTION; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 85018809066     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.02.009     Document Type: Review

References (87)

1. 1 Dienstag, J.L., Hepatitis B virus infection. N Engl J Med 359 (2008), 1486–1500.
2. 2 Liang, T.J., Block, T.M., McMahon, B.J., et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62 (2015), 1893–1908.
3. 3 Hoofnagle, J.H., Reactivation of hepatitis B. Hepatology 49 (2009), S156–S165.
4. 4 Doo, E.C., Hoofnagle, J.H., Rodgers, G.P., NIH consensus development conference: management of hepatitis B. Introduction. Hepatology 49 (2009), S1–S3.
5. 5 Di Bisceglie, A.M., Lok, A.S., Martin, P., et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology 61 (2015), 703–711.
6. 6 Lok, A.S., Ward, J.W., Perrillo, R.P., et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 156 (2012), 743–745.
7. 7 Nagington, J., Reactivation of hepatitis b after transplantation operations. Lancet 1 (1977), 558–560.
8. 8 Hwang, J.P., Vierling, J.M., Zelenetz, A.D., et al. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 20 (2012), 2999–3008.
9. 9 Perrillo, R.P., Gish, R., Falck-Ytter, Y.T., American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 221–244 e3.
10. 10 Reddy, K.R., Beavers, K.L., Hammond, S.P., et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 215–219 quiz e16–e17.
11. 11 Loomba, R., Rowley, A., Wesley, R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148 (2008), 519–528.
12. 12 Yeo, W., Chan, P.K., Zhong, S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000), 299–307.
13. 13 Yeo, W., Chan, P.K., Ho, W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22 (2004), 927–934.
14. 14 Yeo, W., Chan, P.K., Hui, P., et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70 (2003), 553–561.
15. 15 Yeo, W., Johnson, P.J., Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006), 209–220.
16. 16 Lok, A.S., McMahon, B.J., Chronic hepatitis B: update 2009. Hepatology 50 (2009), 661–662.
17. 17 Tohme, R.A., Bulkow, L., Homan, C.E., et al. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol 58 (2013), 396–400.
18. 18 Borentain, P., Colson, P., Coso, D., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 17 (2010), 807–815.
19. 19 Hayashi, K., Ishigami, M., Ishizu, Y., et al. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol 51 (2016), 1081–1089.
20. 20 Puoti, M., Torti, C., Bruno, R., et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44 (2006), S65–S70.
21. 21 De Monte, A., Courjon, J., Anty, R., et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 78 (2016), 27–30.
22. 22 Koh, C., Canini, L., Dahari, H., et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15 (2015), 1167–1174.
23. 23 Evens, A.M., Jovanovic, B.D., Su, Y.C., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22 (2011), 1170–1180.
24. 24 Mozessohn, L., Chan, K.K., Feld, J.J., et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 22 (2015), 842–849.
25. 25 Paul, S., Saxena, A., Terrin, N., et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 30–40.
26. 26 Kim, M.K., Ahn, J.H., Kim, S.B., et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 22 (2007), 237–243.
27. 27 Esteve, M., Saro, C., Gonzalez-Huix, F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004), 1363–1365.
28. 28 Lan, J.L., Chen, Y.M., Hsieh, T.Y., et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70 (2011), 1719–1725.
29. 29 Chung, S.J., Kim, J.K., Park, M.C., et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36 (2009), 2416–2420.
30. 30 Fanouriakis, A., Vassilopoulos, D., Repa, A., et al. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) 53 (2014), 195–196.
31. 31 Kato, M., Atsumi, T., Kurita, T., et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. J Rheumatol 38 (2011), 2209–2214.
32. 32 Lee, Y.H., Bae, S.C., Song, G.G., Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31 (2013), 118–121.
33. 33 Perez-Alvarez, R., Diaz-Lagares, C., Garcia-Hernandez, F., et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90 (2011), 359–371.
34. 34 Koskinas, J., Tampaki, M., Doumba, P.P., et al. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 168 (2013), 679–680.
35. 35 Nakano, N., Kusumoto, S., Tanaka, Y., et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res 44 (2014), 354–357.
36. 36 Ikeda, K., Shiga, Y., Takahashi, A., et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 47 (2006), 155–157.
37. 37 Lai, G.M., Yan, S.L., Chang, C.S., et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 19 (2013), 1318–1321.
38. 38 Lakhani, S., Davidson, L., Priebat, D.A., et al. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2 (2008), 498–499.
39. 39 Beysel, S., Yegin, Z.A., Yagci, M., Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma. Turk J Gastroenterol 21 (2010), 197–198.
40. 40 Li, J., Huang, B., Li, Y., et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 56 (2015), 1710–1717.
41. 41 Ritchie, D., Piekarz, R.L., Blombery, P., et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94 (2009), 1618–1622.
42. 42 Yeo, W., Zee, B., Zhong, S., et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90 (2004), 1306–1311.
43. 43 Calabrese, L.H., Zein, N.N., Vassilopoulos, D., Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65 (2006), 983–989.
44. 44 Kudo, M., Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer 6 (2016), 1–12.
45. 45 Seeger, C., Mason, W.S., Molecular biology of hepatitis B virus infection. Virology 479–480 (2015), 672–686.
46. 46 Yan, H., Zhong, G., Xu, G., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 1, 2012, e00049.
47. 47 Bock, C.T., Schwinn, S., Locarnini, S., et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 307 (2001), 183–196.
48. 48 Pollicino, T., Belloni, L., Raffa, G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130 (2006), 823–837.
49. 49 Belloni, L., Pollicino, T., De Nicola, F., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 106 (2009), 19975–19979.
50. 50 Seeger, C., Mason, W.S., Hepatitis B virus biology. Microbiol Mol Biol Rev 64 (2000), 51–68.
51. 51 Rehermann, B., Ferrari, C., Pasquinelli, C., et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996), 1104–1108.
52. 52 Werle-Lapostolle, B., Bowden, S., Locarnini, S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
53. 53 Sung, J.J., Wong, M.L., Bowden, S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128 (2005), 1890–1897.
54. 54 Zhu, Y., Yamamoto, T., Cullen, J., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75 (2001), 311–322.
55. 55 Rehermann, B., Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19 (2013), 859–868.
56. 56 Guidotti, L.G., Chisari, F.V., Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 (2006), 23–61.
57. 57 Maini, M.K., Gehring, A.J., The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 64 (2016), S60–S70.
58. 58 Lowenberg, M., Verhaar, A.P., van den Brink, G.R., et al. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 13 (2007), 158–163.
59. 59 Azzi, J.R., Sayegh, M.H., Mallat, S.G., Calcineurin inhibitors: 40 years later, can't live without. J Immunol 191 (2013), 5785–5791.
60. 60 Bandzar, S., Gupta, S., Platt, M.O., Crohn's disease: a review of treatment options and current research. Cell Immunol 286 (2013), 45–52.
61. 61 Hwang, Y.G., Moreland, L.W., Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. Curr Rheumatol Rep, 16, 2014, 417.
62. 62 Lucifora, J., Xia, Y., Reisinger, F., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
63. 63 Pers, Y.M., Jorgensen, C., Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Immunotherapy 8 (2016), 1091–1096.
64. 64 Engelhard, M., Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clin Immunol 172 (2016), 101–104.
65. 65 Dokmanovic, M., Clarke, C., Marks, P.A., Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5 (2007), 981–989.
66. 66 Chueh, A.C., Tse, J.W., Togel, L., et al. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal 23 (2015), 66–84.
67. 67 Tropberger, P., Mercier, A., Robinson, M., et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A 112 (2015), E5715–E5724.
68. 68 Abram, C.L., Lowell, C.A., The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 27 (2009), 339–362.
69. 69 Marra, F., Tacke, F., Roles for chemokines in liver disease. Gastroenterology 147 (2014), 577–594 e1.
70. 70 Rowinsky, E.K., The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 55 (2004), 433–457.
71. 71 Khokhar, O.S., Farhadi, A., McGrail, L., et al. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 55 (2009), 69–75.
72. 72 European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
73. 73 Hwang, J.P., Somerfield, M.R., Alston-Johnson, D.E., et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 33 (2015), 2212–2220.
74. 74 Sarin, S.K., Kumar, M., Lau, G.K., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10 (2016), 1–98.
75. 75 Saab, S., Dong, M.H., Joseph, T.A., et al. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 46 (2007), 1049–1056.
76. 76 Kohrt, H.E., Ouyang, D.L., Keeffe, E.B., Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24 (2006), 1003–1016.
77. 77 Huang, H., Li, X., Zhu, J., et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312 (2014), 2521–2530.
78. 78 Hilgendorf, I., Loebermann, M., Borchert, K., et al. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. Bone Marrow Transplant 46 (2011), 1274–1275.
79. 79 Chen, W.C., Cheng, J.S., Chiang, P.H., et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PLoS One, 10, 2015, e0131545.
80. 80 Huang, Y.H., Hsiao, L.T., Hong, Y.C., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31 (2013), 2765–2772.
81. 81 Ho, E.Y., Yau, T., Rousseau, F., et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int 9 (2015), 224–230.
82. 82 Zhang, M.Y., Zhu, G.Q., Shi, K.Q., et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 7 (2016), 30642–30658.
83. 83 Zurawska, U., Hicks, L.K., Woo, G., et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30 (2012), 3167–3173.
84. 84 Wong, W.W., Hicks, L.K., Tu, H.A., et al. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 151 (2015), 639–652.
85. 85 Visram, A., Chan, K.K., McGee, P., et al. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One, 10, 2015, e0120749.
86. 86 Ceccarelli, L., Salpini, R., Sarmati, L., et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect 65 (2012), 180–183.
87. 87 Myers, R.P., Swain, M.G., Urbanski, S.J., et al. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 15 (2001), 599–603.